STOCK COMPARISON
Zimmer Biomet Holdings vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Zimmer Biomet Holdings (ZBH) and Abbott Laboratories (ABT) compare, as of Aug 8, 2026.
As of Aug 8, 2026, Fair Value Calculator sees Zimmer Biomet Holdings as the less overvalued of the two: Zimmer Biomet Holdings trades at $97.19 versus a fair value of $80.19 (-17%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Zimmer Biomet Holdings
ZBH · USD · Health Care
-17%
upside to fair value
overvalued
Price$97.19
Fair Value$80.19
Quality64/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality64/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Zimmer Biomet HoldingsAbbott Laboratories
Valuation
22.6×P/E (TTM)27.7×
2.05×P/S (TTM)3.89×
1.36×P/B3.36×
9.1×EV/EBITDA15.1×
0.62×PEG1.47×
1.1%Dividend yield—
$0.96Dividend per share—
Profitability
9%Net margin14%
20%Operating margin13%
6%Return on equity12%
4%Return on assets6%
Growth
9%Revenue growth (YoY)8%
5.9%Avg. growth/yr (3Y)0.5%
6.1%Avg. growth/yr (5Y)5.1%
Balance & size
0.55×Debt / equity0.19×
$17BMarket cap$175B
healthyGrowth qualityhealthy
Zimmer Biomet Holdings leads: 9 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Zimmer Biomet Holdingsof which business quality 63 · market factors 61
Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
33
50
Quality GrowthAre margins and returns improving?
31
47
CashflowEarnings quality: real cash, not paper profit
84
71
Fin. StrengthBalance sheet, leverage, solvency risk
54
80
InvestmentDisciplined investing over empire-building
90
65
Low VolatilityCalm price path (market factor)
80
83
MomentumPrice trend over the last 3–12 months (market factor)
53
40
52W MomentumDistance to the 52-week high (market factor)
54
34
Net IssuanceBuybacks instead of dilution
100
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Zimmer Biomet Holdings
DCF Models$82.81
Earnings-Based$28.56
Dividend Discount$16.49
Multiples$67.44
Asset-Based$44.00
Growth DCF$81.81
Economic Profit$44.92
Growth Earnings$62.32
22 of 26 models see the stock below the current price.
Abbott Laboratories
DCF Models$70.99
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$69.29
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$64.43
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Zimmer Biomet Holdings
Bear $47.58Fair Value $80.19Bull $100
$97.19 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Zimmer Biomet Holdings · Health Care
Quality score64 · Top 25%
Fair value upside-17% · above median
Abbott Laboratories · Health Care
Quality score64 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 8, 2026, Fair Value Calculator sees Zimmer Biomet Holdings as the less overvalued of the two: Zimmer Biomet Holdings trades at $97.19 versus a fair value of $80.19 (-17%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (64/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
